Browsing by Subject "Meningioma"
Now showing 1 - 9 of 9
Results Per Page
Sort Options
- PublicationOpen AccessAn ultratructural and immunohistochemical study of extracellular matrix in meningiomas(Murcia : F. Hernández, 1990) Hisashi Nitta; Tetsumori Yamashima; Junkoh Yamashita; Toshihiko KubotaExtracellular matrix of meningiomas was studied by light and electron microscopy with the aid of immunohistochemical techniques. Special attention was paid to the distribution of type 1,111, IV, V collagens and laminin with a comparison between meningothelial and fibroblastic types. Connective tissue fibers and basement membrane were not found among the tumor cells in the meningothelial type, but were found in the fibroblastic type. The immunolocalizations were consistently demonstrated extracellularly, but were not within the cytoplasm. Type 1, 111 and V collagens were usually demonstrated in the fibrous septum in the meningothelial type, while they were localized among the tumor cells in the fibroblastic type. Furthermore, type IV collagen and laminin were demonstrated within the vascular walls or around the syncytium in the meningothelial type, while they were localized among the tumor cells in the fibroblastic type. In both types the expression of type IV collagen and laminin was closely related to the distribution of basement membrane. Although meningothelial and fibroblastic meningiomas showed quite different distribution of extracellular matrices, the profile of collagen types expressed by these two basic types was essentially the same. The cellular derivation of meningiomas was discussed with particular attention to the structure of human arachnoid villi and meninges.
- PublicationOpen AccessAtypical meningioma: Histopathological, genetic, and epigenetic features to predict recurrence risk(Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2024) Marastoni, Elena; Barresi, ValeriaGrading assessed according to World Health Organization (WHO) criteria is a major prognostic factor for determining the risk of recurrence in patients with meningiomas and establishing the most appropriate therapeutic strategy after surgery. However, the main issue is to predict the recurrence risk of WHO grade 2 meningioma and, more specifically, of the atypical subtype. Indeed, owing to a reported recurrence rate of 50%, either radiotherapy or observation is currently considered an option after gross total surgical resection of atypical meningiomas. These heterogeneous clinical outcomes are likely related to the broad histopathological diagnostic criteria for this subtype, and whether meningiomas with only brain invasion should be classified as atypical remains controversial. Over the last few years, several studies have shown that DNA methylation profiling, next-generation sequencing, and transcriptomics can better stratify meningiomas for their recurrence risk than histology. The main limitations to the widespread use of these approaches to classify meningiomas are their high cost and the need for sophisticated technologies. However, all studies concurred that atypical meningiomas without chromosome 1p deletion display a low recurrence risk, suggesting that the assessment of this cytogenetic alteration could represent an easy and quick method to determine which patients could benefit from adjuvant treatment after surgery. In addition, prognostically unfavorable molecular groups can be distinguished using specific immunostainings, although further validation is required.
- PublicationOpen AccessClinico-pathological correlations in meningiomas, a DNA and immunohistochemical study(Murcia : F. Hernández, 1993) Cruz-Sánchez, F. F.; Miquel, R.; Rossi, M.L.; Figols, J.; Palacín, A.; Cardesa, AntonioWe have studied 41 meningiomas classified histologically as benjgn, atypical or anaplastic. There were 26 females and 15 males and the mean age was 53 years. 36 tumours were supratentorial, 4 infratentorial and one spinal. Flow cytometry was performed on paraffin-embedded tissue using a selective staining technique for DNA. The ploidy index of DNA and percentage of cells in the S and G2/M phases were calculated. Results were correlated with clinical, histological and immunohistological data. 16/41 tumours . were found to be diploid, 17/41 aneuploid and 8/41 could not be analysed. Significant correlations were found between aneuploid tumours and some qualitative features such as recurrence, pleomorphism, high cellular density, mitotic activity and brain and soft tissue infiltration. A high proliferative index appeared to be associated with clinical aggressiveness. No particular correlation between the expression of cytokeratin and epithelial membrane antigen markers and flow cytometry was found. Our results suggest that DNA flow cytometry in meningiomas may be of value in predicting the behaviour of these neoplasms and confirm that epithelial pattern in meningiomas is not linked to increased anaplasia or poor prognosis.
- PublicationOpen AccessClinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II(Murcia : F. Hernández, 2010) Ruiz, Juan; Martínez, Armando; Hernández, Susana; Zimman, Horacio; Ferrer, Milagros; Fernández, Cristina; Sáez, Mamen; López-Asenjo, José A.; Sanz Ortega, JuliánThe WHO grading scheme distinguishesbenign (grade I), atypical (grade II) and anaplastic(grade III) meningiomas. Both atypical and anaplasticmeningiomas exhibited an overall increased rate ofrecurrence, but between 15-20% benign meningiomaswill also exhibit an unfavourable clinical course withrecurrence before 10 years despite aggressive surgery.We investigated 247 cases of meningiomas grade I andII. The immunohistochemical expression of 30 differentmolecular biomarkers of cell adhesion molecules, cell-cycle and apoptosis regulators and checkpoints wasanalyzed. We also determined apoptosis by in-situhybridization (APOPDETEK™) and loss ofchromosome 1p36 by FISH. The study revealed astatistically significant co-variation (p<0.05) betweenmeningiomas grade II associated with severalclinicopathological features (Simpson grade of clinicalresection, necrosis, nuclear atypia, macronucleoli,transition to small cell, sheet-like growth, highcellularity), increased expression of several biomarkersof tumour proliferation (Cyclin A, Cyclin E, MIB-1 orMDM2), proteases (Cathepsin D) or cell-adhesion(CD44) and lower expression of progesterone receptorsthan meningiomas grade I. The presence of Psammomabodies or the location at convexity were protectiveprognostic factors for tumour recurrence while highcellularity and early age of onset (<57 year-old) wereindicators of increased recurrence risk. The expressionof COX-2, γ-catenin, Topoisomerase IIa, VEGF andMIB-1 was significantly higher in the cohort of recurrentmeningiomas. Meningiomas with chromosome 1p36 lossshowed a higher recurrence rate (33.3%) than meningiomas with normal chromosome 1p36 (18%).Increased COX-2 expression in recurrent meningiomamay also suggest a putative role of COX-2 inhibitors asa chemopreventive treatment for recurrence.
- PublicationOpen AccessInfluence of preoperative dexamethasone therapy on proliferating cell nuclear antigen (PCNA) expression in comparison to other parameters in meningiomas(Murcia : F. Hernández, 1992) Gottschalk, J.; Goebel, S.; Jautzke, G.; Martín, H.; Zimmer, C.; Marzheuser-Brands, S.; Cervós-Navarro, J.We conducted a trial in 42 benign and malignant meningiomas to assess a possible influence of preoperative dexamethasone therapy on mitotic index, labelling indices of proliferating cell nuclear antigen (PCNA), progesterone receptor, epidermal growth factor receptor (EGF-R), c-erbB-2 oncoprotein, cathepsin D, gamma-gamma enolase as well as the mean number of silver-stained nucleolar organizer region-associated proteins (AgNORs). Tumors with preceding dexamethasone therapy for more than 1 day display significantly less immunohistochemical staining for PCNA. A correlation between the labelling index of PCNA and the degree of malignancy could not be identified. There was no significant effect of preoperative dexamethasone therapy on the other parameters. Our data suggest that dexarnethasone may selectively inhibit the expression of PCNA in the GlISphase of the cell cycle. Thus, we emphasize the necessity to heed factors, e.g. dexamethasone, which may affect the expression of proliferating markers.
- PublicationOpen AccessLectin histochemistry of human meningiomas(Murcia : F. Hernández, 1994) Marafioti, T.; Barresi, G.; Batolo, D.The lectins Peanut agglutinin (PNA), Canavalia ensiformis (Con A), Ulex europaeusl (UEAl), Dolichos biflorus (DBA), Triticum vulgaris (WGA) were studied in a series of 36 meningiomas (16 meningotheliomatous-including 3 recurrences, 7 transitional, 4 angiomatous, 2 ((hemangiopericytic~3, papillary-including 1 recurrence, 4 anaplastic-including 3 recurrences. PNA binds to all cases of meningotheliomatous, transitional, papillary and anaplastic meningiomas (including recurrent cases) but the staining is more intense in tumor cells of anaplastic and papillary type. A semiquantitative study showed differences of PNAreactivity in the different subtypes of meningiomas. In meningotheliomatous meningiomas PNA-positivity was encountered in numerous neoplastic cells (50%), whereas papillary and anaplastic subtypes expressed strong cytoplasmic staining of few tumor cells (C 5%). Con A shows the same pattern of reactivity described for PNA, but more weakly. Our results suggest that PNA is a marker of differentiation in meningiomas rather than malignant transformation and can have prognostic relevance.
- PublicationOpen AccessMitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas(Murcia : F. Hernández, 2003) Konstantinidou, A.E.; Korkolopoulou, P.; Kavantzas, N.; Mahera, H.; Thymara, I.; Kotsiakis, X.; Perdiki, M.; Patsouris, Efstratios; Davaris, P.The expression of mitosin, a novel proliferation-associated molecule was evaluated immunohistochemically in a consecutive series of 47 patients with primary intracranial benign and atypical meningiomas. Mitosin expression was correlated with proliferation markers Ki-67 (MIB-1), proliferating cell nuclear antigen (PCNA), topoisomerase IIa (TopoIIa) and mitotic index, as well as with standard clinicopathological parameters and patient outcome. Seven tumors recurred (14.8%) following gross total resection, within a follow-up period ranging from 21 to 108 months (median 60 months). The higher proliferation indices were obtained with mitosin and PCNA and the lower ones with TopoI?a. Mitosin labeling index (LI) ranged from 0.1 to 57% (median 3%), with a significant overlapping of values between grades. A significant positive correlation was shown between mitosin LI on the one hand and Ki-67 LI (p<0.001), or the mitotic index (p=0.027) on the other. The incidence of recurrence was higher in cases with a mitosin LI higher than 3% (p=0.048). Univariate analysis disclosed mitosin LI (p=0.033) along with the mitotic index (p=0.024) and tumor size (p=0.028) as significant predictors of shortened recurrence-free survival. In multivariate analysis, the labeling indices of mitosin (p=0.035) and Ki-67 (p=0.032), along with tumor size, were shown to provide independent prognostic information, beyond that obtained by standard clinical and pathological parameters. However, as indicated by factor analysis, the prognostic information yielded by mitosin was superior to that provided by the remaining proliferation markers (p=0.041). We conclude that mitosin immunohistochemical expression, although failing to discriminate between benign and atypical meningiomas, may be of use as a novel cell proliferation marker and as a predictor of tumor recurrence.
- PublicationOpen AccessPrognostic significance of ACADL and MCM2 in meningiomas: Current evidence and clinical implications(2026) Fabio Agistri; Valeria Barresi; Alberto Pietrantoni; Biología Celular e Histología; Universidad de Murcia, Departamento de Biologia Celular e HistiologiaThis review summarizes the current evidence on the expression and prognostic significance of acyl CoA dehydrogenase long-chain (ACADL) and mini chromosome maintenance 2 (MCM2) in meningiomas. Meningiomas, which comprise approximately 41% of intracranial tumors, are classified by the World Health Organization into 15 histological subtypes and three grades of malignancy. However, owing to the biological heterogeneity within tumors of the same grade, alternative classifications based on molecular features have been proposed. One of these classifies menin giomas into four prognostically relevant molecular groups: immunogenic, benign NF2-wildtype, hyper metabolic, and proliferative. The latter two groups have the worst clinical outcomes and are enriched in ACADL and MCM2 expression, suggesting their potential as immunohistochemical surrogates. The revision of the current literature on the expression of these markers in meningiomas indicates their likely unsuitability as surrogates for molecular groups. However, MCM2 expression was consistently associated with aggressive histopathological features and reduced recurrence-free survival, emerging as a promising independent prognostic marker. ACADL also showed negative prognostic relevance, but with limited data, predominantly in grade 2 meningiomas. Both markers correlated with higher WHO grades but lacked standardized assessment criteria, limiting their clinical application. While ACADL and MCM2 immuno expression does not reliably substitute molecular classification, MCM2, in particular, holds potential for routine prognostic use pending further validation and standardization of immunohistochemical protocols.
- PublicationOpen AccessThe prognostic value of H3 K27me3 in meningiomas: A review on current evidence and methodological challenges(2025) Pietrantoni, Alberto; Barresi, ValeriaMeningiomas are the most common primary intracranial neoplasms. Although they mostly exhibit a benign course, some cases recur after surgery and show high morbidity and mortality rates. In addition to currently established prognostic factors, such as the extent of surgical resection and tumor grade assessed according to World Health Organization (WHO) criteria, the prognostic significance of the immunohistochemical loss of Histone 3 trimethylation in Lysine 27 (H3 K27me3) has emerged in meningiomas. This review examined original studies that analyzed the immunohistochemical expression of H3 K27me3 in meningiomas and its correlation with various features, including overall survival (OS), recurrence-free survival (RFS), and WHO grade. A literature search was conducted in PubMed for English-language publications up to July 8, 2024. Sixteen studies were included in this review. In summary, current evidence indicates that H3 K27me3 loss is more frequent in tumors exhibiting higher biological aggressiveness, as reflected by a significant association with a higher WHO grade, proliferative index, and prognostically unfavorable methylation classes. In addition, published studies consistently indicate a negative prognostic significance for progression-recurrence-free survival (PFS/RFS) in WHO grade 2 meningiomas and OS in WHO grade 3 tumors. However, the lack of a standardized definition for H3 K27me3 loss significantly hampers the incorporation of the H3 K27me3 immunohistochemical assay into routine practice to establish the prognosis of meningiomas.